Hims & Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal
This image was generated by AI and may not depict real events.
Hims & Hers shares surged 9% as investors bet on the company's peptide pipeline and a partnership with Novo Nordisk to distribute Wegovy. The stock has risen 49% in the past five trading sessions ahead of its May 11 earnings report.
Hims & Hers Health shares rose 9% to $31 on Monday, continuing a 49% surge over the past five trading sessions. The gain comes ahead of the company's May 11 earnings report. A partnership with Novo Nordisk to distribute Wegovy has driven enthusiasm, giving Hims & Hers a position in the GLP-1 market beyond compounded alternatives. The company has invested in manufacturing infrastructure, including over 1 million square feet of U.S. facility space. Hims & Hers is also benefiting from renewed FDA interest in peptide drugs, with plans to launch a longevity specialty in 2026 featuring peptides. The company's Q1 EPS is expected to decline 70% year-over-year.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.